{"product_id":"gehealthcare-swot-analysis","title":"GE HealthCare Technologies SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGE HealthCare’s SWOT highlights robust imaging and diagnostics leadership and recurring-service revenue, balanced by regulatory exposure and post-merger integration risks; emerging AI and remote monitoring present clear growth avenues. Purchase the full SWOT analysis to access a professionally formatted Word report and editable Excel matrix with research-backed insights, financial context, and strategic recommendations to support investing, planning, or pitching.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading Market Position in Medical Imaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGE HealthCare holds a top-tier global position in MRI, CT, and PET, backed by decades of engineering and a broad hardware pipeline; by Q4 2025 its imaging revenue reached $7.2B YTD, with MRI\/CT unit share ~22% global and PET growth of 14% YoY, capturing notable share gains in North America and APAC where sales grew 18% and 26% respectively.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMassive Global Installed Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGE HealthCare supports an installed base of over 4 million systems worldwide, generating predictable recurring revenue—services and software made up ~37% of 2024 revenue of $20.5B—enabling high-margin service contracts and regular software updates that increase retention; the footprint also provides a low-cost channel to cross-sell new diagnostics and digital solutions, contributing to a 2024 installed-base service margin above 25%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration of Artificial Intelligence and Digital Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGE HealthCare’s Edison platform, backed by $1.2B in R\u0026amp;D since 2019, made the company a leader in AI-driven clinical decision support by 2025, boosting diagnostic accuracy and cutting readmission-related costs by up to 12% in pilot hospitals.\u003c\/p\u003e\n\u003cp\u003eThese digital tools streamline workflows—Edison deployments reduced imaging turnaround time by 30% on average—creating a strong operational moat versus legacy vendors.\u003c\/p\u003e\n\u003cp\u003eAs of 2025, GE HealthCare held one of the largest portfolios of FDA-cleared AI medical device algorithms, with over 70 clearances, supporting adoption and recurring software revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominance in Pharmaceutical Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Pharmaceutical Diagnostics unit supplies contrast media and molecular imaging agents, generating roughly $1.2B of GE HealthCare revenue in 2024 and supporting high gross margins above 45% thanks to specialized sterile manufacturing and complex regulatory approvals.\u003c\/p\u003e\n\u003cp\u003eHigh technical and regulatory barriers limit new entrants, preserving pricing power and aligning the segment with precision care by improving targeted diagnostics and therapy selection; PET tracer sales grew ~8% in 2024, boosting downstream therapeutic uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue ~ $1.2B\u003c\/li\u003e\n\u003cli\u003eGross margins \u0026gt;45%\u003c\/li\u003e\n\u003cli\u003ePET tracer sales +8% in 2024\u003c\/li\u003e\n\u003cli\u003eHigh regulatory\/technical barriers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Research and Development Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpge healthcare invests about annually in r keeping it at the vanguard of medtech innovation and accelerating products like photon-counting ct handheld ultrasound.\u003e\n\u003cpits focus on photon-counting ct and portable ultrasound secures a tech lead over smaller rivals supported by global scientists engineers solving complex clinical needs.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e2024 R\u0026amp;D spend: ~$1.4B\u003c\/li\u003e\n\u003cli\u003ePhoton-counting CT: commercial launches 2023–24\u003c\/li\u003e\n\u003cli\u003eHandheld ultrasound: expanding point-of-care share\u003c\/li\u003e\n\u003cli\u003e~10,000 global R\u0026amp;D staff\u003c\/li\u003e\n\n\u003c\/pits\u003e\u003c\/pge\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGE HealthCare: Imaging Leader—$7.2B YTD, 4M Systems, 70+ FDA AI Clears\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGE HealthCare leads global imaging (MRI\/CT\/PET ~22% share) with 2025 imaging YTD revenue $7.2B, 4M installed systems, services\/software ~37% of 2024 $20.5B revenue, R\u0026amp;D ~$1.4B (2024), Edison AI with 70+ FDA clearances, pharma diagnostics ~$1.2B (2024) and gross margins \u0026gt;45%, photon-counting CT launches 2023–24.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImaging rev (YTD 2025)\u003c\/td\u003e\n\u003ctd\u003e$7.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled base\u003c\/td\u003e\n\u003ctd\u003e4M systems\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$20.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\/software\u003c\/td\u003e\n\u003ctd\u003e37%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA AI clearances\u003c\/td\u003e\n\u003ctd\u003e70+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma diagnostics (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma gross margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT framework that highlights GE HealthCare Technologies’s core strengths in medical imaging and AI-driven diagnostics, exposes operational and regulatory weaknesses, and maps growth opportunities in digital health and emerging markets alongside competitive and supply-chain threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of GE HealthCare Technologies to accelerate strategic decisions and stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt Obligations Post-Spin-Off\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePost-spin-off from General Electric, GE HealthCare carried about $8.9 billion in net debt at separation and reported a debt\/EBITDA near 3.2x by Q4 2025, showing improvement but remaining elevated.\u003c\/p\u003e\n\u003cp\u003eInterest expense of roughly $550 million in FY 2025 consumed cash that might fund R\u0026amp;D or capital expenditure, constraining reinvestment options.\u003c\/p\u003e\n\u003cp\u003eHigh leverage reduces financial flexibility during downturns or rising rates, raising refinancing and covenant risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Capital Expenditure Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa large portion of ge healthcare technologies revenue comes from high-ticket imaging and diagnostics equipment making it sensitive to hospital capital budgets in product sales software were about total heightening exposure. hospitals under financial stress often defer ct replacements expenditure deferrals caused orders swing year-over-year past cycles earnings cyclicality stock volatility.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Margin Lags Compared to Pure-Play Peers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDespite lean manufacturing gains, GE HealthCare's 2024 adjusted operating margin was about 12.1%, trailing pure-play medtech peers like Abbott (18.5%) and Stryker (20.2%), reflecting overhead from diverse lines spanning ultrasound to pharmaceutical diagnostics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Complex Global Supply Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe production of ge healthcare technologies advanced devices relies on a complex global web for semiconductors and specialty parts chip shortages in raised component lead times by pushed oem logistics costs up squeezing near margins.\u003e\n\u003cpgeopolitical shifts china export controls and eu trade tensions costly re dual moves ge healthcare reported supply related incremental costs in\u003e\n\u003cpsuch vulnerabilities risk delivery delays warranty exposure and quarterly revenue volatility especially for imaging monitoring segments where single parts are common.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30–60% longer lead times (2021–22)\u003c\/li\u003e\n\u003cli\u003e~15% higher logistics costs (2023)\u003c\/li\u003e\n\u003cli\u003e$250–400M incremental supply costs (2024)\u003c\/li\u003e\n\u003cli\u003eHigh single‑source risk in imaging components\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/psuch\u003e\u003c\/pgeopolitical\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Pension and Legal Liabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGE HealthCare inherited sizable legacy pension and legal liabilities from GE; as of year-end 2024 pension and other postretirement liabilities stood near $6.8 billion, tying up capital and creating funding volatility for management to manage.\u003c\/p\u003e\n\u003cp\u003eActive de-risking has cut funded-status swings but payments and legal reserves still depress free cash flow versus younger medtech peers with lighter balance sheets.\u003c\/p\u003e\n\u003cp\u003eThese obligations raise operational complexity and limit agility for M\u0026amp;A and R\u0026amp;D spending.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 pension+OPEB ≈ $6.8B\u003c\/li\u003e\n\u003cli\u003eReduces FCF and leverage flexibility\u003c\/li\u003e\n\u003cli\u003eRequires ongoing cash contributions and legal reserves\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh leverage and cyclical imaging sales strain margins and cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElevated leverage (net debt $8.9B; debt\/EBITDA ~3.2x Q4 2025) and ~$550M interest in FY2025 limit reinvestment; heavy reliance on high-ticket imaging (equipment\/software $13.7B, ~55% rev 2024) drives cyclical orders; 2024 adjusted margin 12.1% lags peers; supply-chain shocks added $250–400M costs in 2024; pension\/OPEB ≈ $6.8B. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e$8.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~3.2x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest expense FY2025\u003c\/td\u003e\n\u003ctd\u003e$550M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquipment rev 2024\u003c\/td\u003e\n\u003ctd\u003e$13.7B (55%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. op margin 2024\u003c\/td\u003e\n\u003ctd\u003e12.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply extra cost 2024\u003c\/td\u003e\n\u003ctd\u003e$250–400M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePension+OPEB 2024\u003c\/td\u003e\n\u003ctd\u003e$6.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eGE HealthCare Technologies SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report and reflects the same structured, actionable insights on GE HealthCare Technologies. Purchase unlocks the complete, editable file with in-depth strengths, weaknesses, opportunities, and threats for immediate use. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752423895417,"sku":"gehealthcare-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/gehealthcare-swot-analysis.png?v=1772240810","url":"https:\/\/growthsharematrix.com\/products\/gehealthcare-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}